U
WX

UBS’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

UBS’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$7K Buy
+200
New +$6.86K ﹤0.01% 9232
2014
Q2 		– Sell
-800
Closed -$29K – 11201
2014
Q1 		$29K Buy
800
+200
+33% +$7.34K ﹤0.01% 7615
2013
Q4 		$23K Buy
+600
New +$18.9K ﹤0.01% 7997

Other funds holding WX

Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

UBS's WX Position: Q3 2014 in Review

UBS reduced its WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) stake by 24% in Q3 2014, selling an estimated $772K and leaving 72,267 shares worth $2.53M. The position accounts for ﹤0.01% of the portfolio, ranked #2680.

UBS first reported a position in WX in Q2 2013 and has held it in 6 quarters since. The position peaked at $3.4M in Q1 2014. 157 funds tracked by Wall St. Rank hold WX as of Q3 2014.

  • UBS held 72,267 shares of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS worth $2.53M as of Q3 2014.
  • UBS sold 22,528 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q3 2014, an estimated $772K.
  • WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS made up ﹤0.01% of UBS's portfolio in Q3 2014, its #2680 holding.
  • UBS first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2013 and has held it in 6 quarters since.
  • UBS's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $3.4M in Q1 2014.
  • 157 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.